Patent · US Active

Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

US8211904B2 · kind B2 · utility

1Cited by

5References

17Claims

0Family size

Assignees

Merck Sharp & Dohme LLC · US
Sunesis Pharmaceuticals, Inc. · US

Inventors

Craig A. Coburn · Royersford, US
Melissa Egbertson · Ambler, US
Samuel L. Graham · Schwenksville, US
Georgia B. McGaughey · Harleysville, US
Shaun R. Stauffer · Brentwood, US
Hemaka A. Rajapakse · Wyncote, US
Philippe G. Nantermet · Lansdale, US
Shawn J. Stachel · Perkasie, US
Wenjin Yang · Foster City, US
Wanli Lu · Burlingame, US
Bruce Fahr · Foster City, US

Key dates

Filing date	Jul 14, 2006
Grant date	Jul 3, 2012
Priority date	—
Expiry date	Aug 23, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to spiropiperidine compounds of formula (I)and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.